MetaCap

Armata Pharmaceuticals Inc. (ARMP)

NYSE: ARMPHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD

3.03+0.05 (+1.68%)

At close: Nov 20, 4:00 PM ET · Delayed 15 min

ARMP stock chart

Technical analysis

Key statistics

All statistics
Market cap
$112.69M
EPS (TTM)
-$4.17
52-week range
2.40 – 14.98
Day range
2.89 – 3.19
Volume / Avg
85.64K / 182.52K
Beta
—

52-week range

$2.40$14.98

ARMP stock today

On Nov 20, ARMP ended the session at $3.03, adding $0.05 (1.68%), versus the S&P 500's 3.70% decline. Trading was light, with 85.64K shares changing hands, about 47% of the average daily volume. At this level, ARMP sits near the bottom of its 52-week range of $2.40 to $14.98: 79.8% below the high, set on Apr 22, 2026 and 26.2% above the low.

ARMP is down 51.8% year to date, underperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 56.9%. Armata Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$4.17), so its P/E ratio is not meaningful.

Summary generated from market data by MetaCap's automated system. Methodology

About Armata Pharmaceuticals

Company profile

Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology.

Industry
Biotechnology: Biological Products (No Diagnostic Substances)
CEO
Dr. Deborah L. Birx M.D.
Headquarters
Los Angeles, CA
Employees
61

Financial highlights

Full financials

Armata Pharmaceuticals reported a net loss of $173.8 million, compared with a loss of $18.9 million a year earlier. Diluted earnings per share came in at -$4.80.

Armata Pharmaceuticals annual revenue, net income and EPS
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021
Revenue—————
Growth—————
Net income$-173.80M$-18.92M$-69.05M$-36.92M$-23.16M
EPS (diluted)$-4.80$-0.89$-1.91$-1.08$-0.96

Analyst forecast

Forecast

Consensus (2 analysts)

none

Avg. price target

$17.50+477.56%

  • Strong buy 0
  • Buy 2
  • Hold 0
  • Sell 0
  • Strong sell 0

Target range

Low $15.00High $20.00

Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.

Earnings

Earnings history
Last reported (Sep/2026)
Nov 12, 2026
EPS actual vs est.
$-0.24 vs $-0.57
Surprise
+57.89%

ARMP news

All ARMP news

Armata Pharmaceuticals peers

Health Care sector
ARMP peer companies
CompanyPrice% ChgMarket capCompare
FATEFate Therapeutics Inc.0.919-9.01%$111.82Mvs ARMP
CRDLCardiol Therapeutics Inc. Class A0.8626-2.28%$110.14Mvs ARMP
ENGNenGene Therapeutics Inc.1.74-1.14%$116.61Mvs ARMP
IVVDInvivyd Inc.0.4127-7.45%$122.01Mvs ARMP
HUMAHumacyte Inc.0.4454-17.90%$123.73Mvs ARMP
CMPXCompass Therapeutics Inc.0.6882+1.43%$123.94Mvs ARMP
MOLNMolecular Partners AG ADR2.53-5.25%$96.80Mvs ARMP
IPHAInnate Pharma S.A. ADS0.8634-8.14%$96.44Mvs ARMP

Indexes, lists and sector

Armata Pharmaceuticals stock FAQ

What is Armata Pharmaceuticals's stock price today?

ARMP last traded at $3.03 as of Nov 20, 4:00 PM EST, up 1.68% on the day. Prices are delayed at least 15 minutes.

Does Armata Pharmaceuticals pay a dividend?

No. Armata Pharmaceuticals does not currently pay a regular cash dividend.

Who is Armata Pharmaceuticals's CEO?

Dr. Deborah L. Birx M.D. is the chief executive officer of Armata Pharmaceuticals Inc., which has about 61 employees.

Has ARMP ever split its stock?

Yes. The most recent ARMP stock split was a 1-for-14 split on May 10, 2019, one of 4 splits on record.

What is the ARMP 52-week high?

The 52-week high for ARMP is $14.98 and the 52-week low is $2.40. The stock is currently 79.8% below its high.

Compare ARMP